AMGN vs CODX · P/E 24, rev $36.75B vs rev $3.9M
Amgen Inc (AMGN) versus Co-Diagnostics, Inc. Common Stock (CODX) — a side-by-side from cached financials, not a winner call.
Amgen Inc (AMGN) is a drug manufacturers - general company listed on US.
Co-Diagnostics, Inc. Common Stock (CODX) is a medical devices company listed on US.
Latest reported AMGN revenue for 2025-12-31 was $36.75B. Net income was $7.71B. Revenue was up 10.0% from 2024-12-31 to 2025-12-31. AMGN currently screens at market cap $188.67B and trailing P/E 24.3.
Latest reported CODX revenue for 2024-12-31 was $3.9M. Net income was -$37.6M. Revenue was down 42.5% from 2023-12-31 to 2024-12-31. CODX currently screens at market cap $31.4M.
AMGN currently screens at market cap $188.67B and trailing P/E 24.3. CODX currently screens at market cap $31.4M.
Not investment advice. Open the AMGN and CODX stock pages for the full models.
Not investment advice.